Biomaterials, Biodegradables and Biomimetics Research Group

Papers in Scientific Journals

Biological responses to spider silk-antibiotic fusion protein

Abstract

The development of a new generation of multifunctional biomaterials is a continual goal for the field of materials science. The in vivo functional behaviour of a new fusion protein that combines the mechanical properties of spider silk with the antimicrobial properties of hepcidin was addressed in this study. This new chimeric protein, termed 6mer + hepcidin, fuses spider dragline consensus sequences (6mer) and the antimicrobial peptide hepcidin, as we have recently described, with retention of bactericidal activity and low cytotoxicity. In the present study, mouse subcutaneous implants were studied to access the in vivo biological response to 6mer + hepcidin, which were compared with controls of silk alone (6mer), polylacticglycolic acid (PLGA) films and empty defects. Along with visual observations, flow cytometry and histology analyses were used to determine the number and type of inflammatory cells at the implantation site. The results show a mild to low inflammatory reaction to the implanted materials and no apparent differences between the 6mer + hepcidin films and the other experimental controls, demonstrating that the new fusion protein has good in vivo biocompatibility, while maintaining antibiotic function. Copyright (C) 2011 John Wiley & Sons, Ltd.

Journal
Journal of Tissue Engineering and Regenerative Medicine
Volume
6
Issue
5
Pagination
356-368
Publisher
WILEY-BLACKWELL
ISSN
1932-6254
URL
http://onlinelibrary.wiley.com/doi/10.1002/term.437/abstract
Keywords
Antimicrobial activity, Chimeric protein, Hepcidin, Inflammatory response, Spider silk, Tissue engineering
Rights
Restricted Access
Peer Reviewed
Yes
Status
published
Year of Publication
2012
DOI
DOI: 10.1002/term.437
Date Published
2012-05-01
Search Google ScholarGenerate BibTexDownload RTF
This website uses cookies. By using this website you consent to our use of these cookies. For more information visit our Policy Page.